Observational Study With Mixtard® 30 NovoLet® to Assess Patient Satisfaction

Novo Nordisk

Status: Completed

Conditions: Diabetes Mellitus, Type 1; Diabetes; Diabetes Mellitus, Type 2

Treatments: Drug: biphasic human insulin 30

Study type: Observational

Funder types: Industry

Identifiers

NCT01492218

NOPEN3-1885

Details and patient eligibility

About

This study is conducted in Asia. The aim of this study is to assess patient satisfaction after switching to biphasic human insulin 30 treatment using the NovoLet® insulin device as treatment for diabetes mellitus under normal clinical practice setting.

Enrollment: 1,330 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• Diabetes mellitus (type 1 or type 2)
• Patient not presently using Mixtard® 30 NovoLet®

Trial design

1,330 participants in 1 patient group

NovoLet®

Treatment:

Drug: biphasic human insulin 30